Table of Contents
ISRN Toxicology
Volume 2013 (2013), Article ID 242345, 6 pages
http://dx.doi.org/10.1155/2013/242345
Research Article

Inhibition of Nitric Oxide Synthase by L-NAME Promotes Cisplatin-Induced Nephrotoxicity in Male Rats

1Water & Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan 81745, Iran
2Department of Physiology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
3Isfahan-MN Institute of Basic & Applied Sciences Research, Isfahan 81546, Iran
4Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
5Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan 81745, Iran

Received 26 June 2013; Accepted 28 July 2013

Academic Editors: J. P. Petzer, M. M. Sayed-Ahmed, and D. Wu

Copyright © 2013 Fatemeh Moslemi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Silbiger and J. Neugarten, “The role of gender in the progression of renal disease,” Advances in Renal Replacement Therapy, vol. 10, no. 1, pp. 3–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Ramesh and W. B. Reeves, “p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice,” American Journal of Physiology, vol. 289, no. 1, pp. F166–F174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Nematbakhsh, A. Talebi, H. Nasri et al., “Some evidence for sex-based difference in cisplatin-induced nephrotoxicity in rat,” Clinical and Experimental Medical Letters, vol. 53, no. 1-2, pp. 29–32, 2012. View at Google Scholar
  4. Q. Wei, M.-H. Wang, and Z. Dong, “Differential gender differences in ischemic and nephrotoxic acute renal failure,” American Journal of Nephrology, vol. 25, no. 5, pp. 491–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Stakisaitis, G. Dude-niene, R. J. Jankunas, G. Grazeliene, J. Didziapetriene, and B. Pundziene, “Cisplatin increases urinary sodium excretion in rats: gender-related differences,” Medicina, vol. 46, no. 1, pp. 45–50, 2010. View at Google Scholar
  6. D.-H. Kang, E. S. Yu, K.-I. Yoon, and R. Johnson, “The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection,” American Journal of Pathology, vol. 164, no. 2, pp. 679–688, 2004. View at Google Scholar · View at Scopus
  7. S. Y. Saad, T. A. O. Najjar, M. H. Daba, and A. C. Al-Rikabi, “Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine,” Chemotherapy, vol. 48, no. 6, pp. 309–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Engineer, N. S. Brown, D.-H. W. Ho, R. A. Newman, and R. E. Bulger, “A comparison of the effects of tetraplatin and cisplatin on renal function and gentamicin pharmacology in rats,” Toxicology, vol. 59, no. 2, pp. 151–162, 1989. View at Google Scholar · View at Scopus
  9. R. M. J. Palmer, D. S. Ashton, and S. Moncada, “Vascular endothelial cells synthesize nitric oxide from L-arginine,” Nature, vol. 333, no. 6174, pp. 664–666, 1988. View at Google Scholar · View at Scopus
  10. S. Saleh and E. El-Demerdash, “Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide,” Basic & Clinical Pharmacology & Toxicology, vol. 97, no. 2, pp. 91–97, 2005. View at Google Scholar
  11. R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of cisplatin nephrotoxicity,” Toxins, vol. 2, no. 11, pp. 2490–2518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Ohno, S. Kato, M. Wakatsuki et al., “Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone,” Gynecologic Oncology, vol. 103, no. 1, pp. 94–99, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Endo and H. Kanbayashi, “Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of cisplatin,” Pharmacology & Toxicology, vol. 92, no. 6, pp. 300–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Srivastava, A. Farookh, N. Ahmad, M. Misra, S. K. Hasan, and M. M. Husain, “Evidence for the involvement of nitric oxide in cisplatin-induced toxicity in rats,” BioMetals, vol. 9, no. 2, pp. 139–142, 1996. View at Google Scholar · View at Scopus
  15. F. Eshraghi-Jazi, M. Nematbakhsh, H. Nasri et al., “The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: gender related differences in rat model,” Journal of Research in Medical Sciences, vol. 16, no. 11, pp. 1389–1396, 2011. View at Google Scholar · View at Scopus
  16. Y. Lu, A. Kawashima, I. Horii, and L. Zhong, “Cisplatin-induced cytotoxicity in BSO-exposed renal proximal tubular epithelial cells: sex, age, and species,” Renal Failure, vol. 27, no. 5, pp. 629–633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Wongtawatchai, S. Agthong, A. Kaewsema, and V. Chentanez, “Sex-related differences in cisplatin-induced neuropathy in rats,” Journal of the Medical Association of Thailand, vol. 92, no. 11, pp. 1485–1491, 2009. View at Google Scholar · View at Scopus
  18. M. Haghighi, M. Nematbakhsh, A. Talebi et al., “The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences,” Renal Failure, vol. 34, no. 8, pp. 1046–1051, 2012. View at Google Scholar
  19. M. A. Mansour, A. M. Mostafa, M. N. Nagi, M. M. Khattab, and O. A. Al-Shabanah, “Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats,” Comparative Biochemistry and Physiology C, vol. 132, no. 2, pp. 123–128, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Baylis, B. Mitruka, and A. Deng, “Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage,” Journal of Clinical Investigation, vol. 90, no. 1, pp. 278–281, 1992. View at Google Scholar · View at Scopus
  21. M. Blum, T. Yachnin, Y. Wollman et al., “Low nitric oxide production in patients with chronic renal failure,” Nephron, vol. 79, no. 3, pp. 265–268, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. R. J. Schmidt and C. Baylis, “Total nitric oxide production is low in patients with chronic renal disease,” Kidney International, vol. 58, no. 3, pp. 1261–1266, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. I. Chirino, J. Trujillo, D. J. Sánchez-González et al., “Selective iNOS inhibition reduces renal damage induced by cisplatin,” Toxicology Letters, vol. 176, no. 1, pp. 48–57, 2008. View at Google Scholar
  24. S. Klahr and J. Morrissey, “Renal disease: the two faces of nitric oxide,” Laboratory Investigation, vol. 72, no. 1, pp. 1–3, 1995. View at Google Scholar · View at Scopus
  25. M. O. Ribeiro, E. Antunes, G. de Nucci, S. M. Lovisolo, and R. Zatz, “Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension,” Hypertension, vol. 20, no. 3, pp. 298–303, 1992. View at Google Scholar · View at Scopus
  26. N. Bouriquet and D. Casellas, “Chronic L-NAME hypertension in rats and autoregulation of juxtamedullary preglomerular vessels,” American Journal of Physiology, vol. 269, no. 2, pp. F190–F197, 1995. View at Google Scholar · View at Scopus
  27. T. F. Andoh, M. P. Gardner, and W. M. Bennett, “Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity,” Transplantation, vol. 64, no. 9, pp. 1236–1240, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Schwartz, M. Blum, G. Peer et al., “Role of nitric oxide (EDRF) in radiocontrast acute renal failure in rats,” American Journal of Physiology, vol. 267, no. 3, pp. F374–F379, 1994. View at Google Scholar · View at Scopus
  29. Z. Pezeshki, “Sex-related difference in nitric oxide metabolites levels after nephroprotectant supplementation administration against cisplatin-induced nephrotoxicity in Wistar rat model: the role of vitamin E, erythropoietin, or N-Acetylcysteine,” ISRN Nephrology, vol. 2013, Article ID 612675, 5 pages, 2013. View at Publisher · View at Google Scholar
  30. Z. Pezeshki and M. Nematbakhsh, “Nitric oxide metabolites change in cisplatin-induced nephrotoxicity: the effect of L-Arginine and Losartan,” Journal of Analytical Oncology, pp. 117–119, 2013. View at Publisher · View at Google Scholar
  31. N. S. Bryan, “Nitrite in nitric oxide biology: cause or consequence? A systems-based review,” Free Radical Biology and Medicine, vol. 41, no. 5, pp. 691–701, 2006. View at Publisher · View at Google Scholar · View at Scopus